Drugdiscovery >> Drugs >> News
5182
Views
Orphan drug designation for Bayer’s hypertension drug riociguat - drugdiscovery.com
Orphan drug designation for Bayer’s hypertension drug riociguat - drugdiscovery.com


The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Read More >>


Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension - September 26, 2013
Related Articles
7520
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

6456
Views
Bayer's riociguat approved in two pulmonary hypertension indications Bayer's riociguat approved in two pulmonary hypertension indications
FDA has backed approval of the drug for the treatment of both pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Read More >>

Tags: FDA, approval, Bayer, riociguat, indication, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

5832
Views
Bayer's hypertension drug Adempas approved in Canada Bayer's hypertension drug Adempas approved in Canada
The Health Canada has approved the drug Adempas (riociguat) for the treatment of a severe, progressive and life-threatening condition of the heart and lungs, chronic thromboembolic pulmonary hypertens Read More >>

Tags: Adempas, riociguat, Bayer, hypertension drug, thromboembolic, pulmonary hypertension, Canada, approval

4488
Views
FDA approves Adempas for the treatment of two forms of pulmonary hypertension FDA approves Adempas for the treatment of two forms of pulmonary hypertension
Bayer HealthCare’s drug Adempas (riociguat) is approved by the FDA for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatmen Read More >>

Tags: Adempas, riociguat, treatment, drug, pulmonary hypertension, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

13079
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

6554
Views
ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A
After last week’s approval of Orphan Drug Designation to Alnylam Pharmaceuticals’ RNAi drug ALN-AT3 for the treatment of hemophilia B, this week it is for the treatment of hemophilia A . Read More >>

Tags: orphan, drug, ALN-AT3, Alnylam, RNAi, hemophilia

5866
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

2894
Views
Orphan Drug designation for SGX94 for acute radiation syndrome Orphan Drug designation for SGX94 for acute radiation syndrome
Soligenix’ innate defense regulator, SGX94, is a new class of short, synthetic peptides that accelerates resolution of tissue damage following exposure to a variety of agents including radiation, c Read More >>

Tags: orphan drug, SGX94, acute radiation syndrome, Soligenix, synthetic peptides

13231
Views
Bayer’s new hypertension drug to be approved by FDA Bayer’s new hypertension drug to be approved by FDA
The new drug worked well in clinical trials and is recommended for approval but at lower doses than those proposed by the company. Read More >>

Tags: Bayer, new drug, hypertension, pulmonary hypertension

7985
Views
Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV
FDA has approved an Orphan Drug Designation to Advaxis’ next generation immunotherapy drug ADXS-HPV for the treatment of human papillomavirus (HPV)-associated anal cancer. Read More >>

Tags: Advaxis, ADXS-HPV, HPV, anal cancer, human papillomavirus, immunotherapy, drug

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013